Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
      • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact

News

May 13, 2025Blog | Member News, Healthcare

Merck KGaA Darmstadt Germany to acquire SpringWorks Therapeutics

(Photo via Reuters).

New England Council member, Merck KGaA Darmstadt Germany, recently announced plans to acquire a Connecticut-based bioscience company, SpringWorks Therapeutics. The deal is valued at $3.9 billion, and Merck will pay $47 per share in cash.

SpringWorks Therapeutics is a commercial-stage biotech based in Stamford, Connecticut, developing treatments for rare diseases and cancers. The company’s portfolio includes rare tumor treatments that complement Merck’s developed therapies.

“We have the unique opportunity with SpringWorks to establish a leadership position in rare tumors and build a strong foundation for further investments in this area, where a large unmet medical need exists. Together, our company and SpringWorks are the perfect combination to improve outcomes for patients with rare tumors and bring therapeutic innovations to more patients worldwide while building on and reinforcing the early success of SpringWorks in the United States,” said Peter Guenter, member of the Executive Board and CEO of Healthcare at Merck KGaA, Darmstadt, Germany.

The New England Council congratulates Merck on this acquisition, which will strengthen the company’s healthcare presence in the US and connect more patients with SpringWorks’ therapeutic innovations.

Read more in Merck’s press release, Reuters, and the Hartford Business Journal.

Council Related News
Read Article Blog | Council News, Federal Advocacy, Healthcare

NEC Calls on New England Delegation to Support Bill to Expand Substance Use Disorder Prevention and Treatment

Read Article Blog | Member News, Financial Services

Citizens Bank announces new program: “Citizens for Startups”

Read Article Blog | Member News, Higher Education

Brown University names new dean of the College

Read Article Blog | Member News, Healthcare

Waters Corporation acquires specialized imaging technology from Halo Labs

Read Article Blog | Member News, Healthcare

Sanofi to acquire Vigil Neuroscience, Inc. for $470M

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit